EMJ Hematology 8 [Supplement 4] . 2020

In this issue

The recent 2020 update to the European LeukemiaNet (ELN) recommendations provided insights from new developments and research which have led to changes in the landscape of chronic myeloid leukaemia (CML) treatment. Difficult cases, resistant to an initial second-generation tyrosine kinase inhibitor (TKI) given either as first- or second-line therapy, are now known to be unlikely to have a durable response to an alternative second-generation TKI. The panel recommendation is that these patients, without specific mutations or cardiovascular risk factors, should be started on a third-generation TKI like ponatinib.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given